Palforzia | pharmaphorum

Skip to main content

Monday 23 December 2024

twitter linkedin facebook rss

User account menu

Subscribe

Channels

Content type

Categories

Categories

Sort by

Order

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

close

Channels

Content type

Categories

Categories

Sort by

Order

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

Sign up

twitter linkedin facebook rss

Sign in

Palforzia

News

peanut allergy

Nestle sells underperforming peanut allergy drug

Almost exactly three years after agreeing on a $2.6 billion deal to acquire Aimmune Therapeutics and its peanut allergy therapy Palforzia, food group Nestle has sold off t

News

After FDA snub, DBV charts a new course for Viaskin peanut

After FDA snub, DBV charts a new course for Viaskin peanut

It’s been more than three years since DBV Technologies’ peanuty allergy therapy was

News

peanuts

NICE backs Aimmune's peanut allergy drug Palforzia for child...

Children in England with peanut allergies could be among the first in Europe to get access to Aimmune's oral immunotherapy Palforzia, after the drugmaker agreed a supply deal with NHS Engla

News

peanuts

DBV craters on FDA’s peanut allergy immunotherapy rejection

DBV Technologies’ long and tortuous path to an FDA verdict on its Viaskin Peanut allergy shot has led to another dead end.

News

Halves of roasted peanuts in bowl and near on dark wooden background, top view

FDA approves first ever peanut allergy therapy from Aimmune

The FDA has approved the first ever peanut allergy treatment, backing Aimmune's Palforzia to reduce reactions in children.

Editor's Picks

Novo completes $16.5bn takeover of Catalent

UnitedHealth killing suspect gets first-degree murder charge

Novo sets aside $1.2bn for rare diseases plant

Lilly's Alzheimer's drug Kisunla is cleared in China

PBM reform looms in end-of-year US legislation package

News

PBM reform dropped in Congress' funding package

PBM reform dropped in Congress' funding package

Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

The AI effect in pharma commercial strategy: From data to real-time insight & actions

Sponsored

The AI effect in pharma commercial strategy: From data to re...

Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Subscribe

rss facebook linkedin twitter

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2024, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company